Filing Flows

Filing Flows › Gyre Therapeutics (GYRE) › Who owns the stock

Who owns Gyre Therapeutics (GYRE) stock

49 funds reported Gyre Therapeutics (GYRE) shares in their latest 13F filings, worth $40.8M in all. The largest holder is Vanguard Group ($8.5M). Last quarter 25 funds added to their stakes and 23 cut them.

Largest holders of GYRE (13F)Largest holders of GYRE (13F)Vanguard Group$8.5MBlackRock$6.6MOctagon Capital Advisors LP$6.3MVanguard Capital Management LLC$5.8MGeode Capital Management, LLC$3.5MState Street$1.6MCharles Schwab Investment Managem…$1.2MNorthern Trust$1.1MSBI Securities$1.1MVanguard Fiduciary Trust$996K

Largest holders (13F)

FundSharesValueChangeQuarter
Vanguard Group1,201,589$8.5Mincrease2025-12-31
BlackRock993,943$6.6Mincrease2026-06-30
Octagon Capital Advisors LP954,416$6.3Mnew2026-06-30
Vanguard Capital Management LLC876,927$5.8Mdecrease2026-06-30
Geode Capital Management, LLC532,950$3.5Mincrease2026-06-30
State Street245,402$1.6Mincrease2026-06-30
Charles Schwab Investment Management184,286$1.2Mincrease2026-06-30
Northern Trust169,537$1.1Mincrease2026-06-30
SBI Securities166,750$1.1Mdecrease2026-06-30
Vanguard Fiduciary Trust151,073$996Kincrease2026-06-30
Vanguard Portfolio Management LLC123,953$817Kincrease2026-06-30
Goldman Sachs Group86,235$568Kincrease2026-06-30
Bank of New York Mellon62,750$414Kincrease2026-06-30
Morgan Stanley41,691$275Kincrease2026-06-30
Barclays32,975$242Kincrease2026-09-30

Gyre Therapeutics' latest quarter

Gyre Therapeutics, Q3 2026: revenue $32.9M (+0.7% year over year), operating margin -4.6%, net loss $2.5M, operating cash flow −$4.0M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most GYRE stock?

By the latest 13F filings: Vanguard Group ($8.5M); BlackRock ($6.6M); Octagon Capital Advisors LP ($6.3M); Vanguard Capital Management LLC ($5.8M); Geode Capital Management, LLC ($3.5M).

What is the short interest in GYRE?

1,927,774 shares were sold short at the 2026-10-15 settlement, 0.48% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.